Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.25    0.00 (0.00%)
Bid:
6.00
Ask:
6.50
Spread: 0.50 (8.333%)
Market Cap: £6.46m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Placing and update

22 May 2012 11:30

CERES MEDIA INTERNATIONAL PLC ("Ceres" or the "Company" or the "Group") Placing, update and grant of options Placing

The board announces that the Company, through its broker First Columbus LLP, has placed 21,000,000 new ordinary shares at a price of 1 pence per share ("the Placing Price") raising £210,000 of funds before expenses ("the Placing").

The proceeds of the Placing will be used for general working capital purposes and to support further development of the business.

The Company currently has authority to issue 10,324,556 new ordinary shares for cash and will therefore execute the Placing in two tranches.

The first tranche of 10,000,000 new ordinary shares will occur with immediate effect. Application has been made to the London Stock Exchange for the 10,000,000 new ordinary shares to be admitted to trading on AIM. Trading in these shares is expected to occur on or around 28 May 2012.

Admission of the remaining 11,000,000 new ordinary shares will occur in a second tranche, subject to shareholder approval of further authorities to issue new ordinary shares in the Company for cash. A circular convening a general meeting of the Company ("the General Meeting") will shortly be posted to shareholders seeking, inter alia, such authority.

Proposed Directors' Dealing

The directors of the Company are participating in the second tranche of the Placing, details of each of the directors' participation in the Placing are set out in the table below.

In addition to their participation in the Placing, the directors have agreed to convert certain accrued remuneration costs and unpaid expenses of £84,000 in to 8,400,000 new shares in the Company at the Placing Price ("the Conversion"). Details of the Conversion are set out in the table below. The Conversion will constitute a related party transaction pursuant to the AIM Rules. Shareholders consent in relation to the Conversion will be sought at the General Meeting. A further announcement detailing the related party disclosure will be made subsequent to the General Meeting.

Conditional on shareholder approval at the General Meeting the Company willissue a further 2,000,000 shares in the Company, at the Placing Price, tocertain other creditors in lieu of balances totalling £20,000 ("CreditorConversion").Director Number of Number of Number of Number of % of existing shares Conversion shares enlarged shares held subscribed shares following issued share for in the Placing and capital* Placing Conversion A Dowdeswell 3,527,342 2,617,000 3,000,000 9,144,342 14.9% L Barber 403,089 300,000 4,500,000 5,203,089 8.5% C Garston 379,938 283,000 900,000 1,562,938 2.5%

*assuming the Placing, Conversion and Creditor Conversion occur

Application for admission to trading on AIM of the second tranche of the Placing, the Conversion shares and the Creditor Conversion shares, totalling 21,400,000 new ordinary shares, will occur following the General Meeting.

Following the Placing, Conversion and Creditor Conversion, the so enlarged issued share capital of the Company will comprise 61,373,961 ordinary shares of 1 pence each.

Update

The directors are encouraged by the Group's trading performance since 31 January 2012. As announced on 30 April 2012, the directors remain cautiously optimistic evidenced by the gradual increase in turnover recorded to date in 2012. Orders received in April 2012 were in excess of the total revenues for the 6 months to 31 January 2012.

Sales of NatureWovenTM, ChorusTM and GossypTM, whilst still small by comparison to what the directors believe is their potential, have continued to customers in both the USA and Europe. Additional orders have been received for Nature Netting, the Company's new screening product, for high profile events taking place in the UK during the summer and beyond.

The directors believe that the technical issues surrounding the physical fixing process for the Group's TierraFilmTM Window Cling product have been resolved and this upgraded product is expected to be available in the UK and the USA in June 2012.

Advanced stage testing of the TierraFilmTM Backlit product continues with major `Out of Home' media owners and the Company anticipates approvals shortly. This product boasts excellent print quality combined with superior light diffusion characteristics compared to existing materials used.

Leslie Barber, Chairman, commented: "The indications are that the Company's product portfolio now meets the quality, usage and price requirements of the marketplace and the relevant user base. Distribution gains in the USA and Europe are beginning to show through in sales and the response to NatureNettingTM and BackLit products in the UK is encouraging. The Company looks poised to exploit its unique compostable, recyclable and bio-degradable products in its core markets."

Grant of options

Since the Company's admission to AIM on 13 September 2011, it has agreed to grant options over 960,000 shares ("Admission Options") to directors and key senior management. The terms of the Admission Options are set out below:

Vesting period: None

Exercise period: Any time until 13 September 2020

Exercise price: 1p

Performance criteria: Company's share price in excess of 5 pence per share

Directors' participation in the Admission Options is set out in the table below.

In December 2011, the Company agreed in principal to issue further options to non-executive directors ("Further Options") with the objective of conserving cash resources. Conditional on the granting of the Further Options, the non-executive directors have agreed to waive the cash element of their remuneration and convert existing remuneration liabilities into shares in the Company.

The terms of the Further Options are set out below:

Vesting period: None

Exercise period: Any time until 13 September 2020

Exercise price: 1p

Performance criteria: None

Directors' participation in the Further Options is set out in the table below.

Director Admission Further Total Options Options A Dowdeswell 500,000 nil 500,000 L Barber 300,000 2,500,000 2,800,000 C Garston nil 1,000,000 1,000,000 Others 160,000 nil 160,000

With the exception of the options granted to C Garston, which are issued by way of an unapproved scheme, all other options are issued under an EMI scheme.

The grant of the Admission Options and Further Options to directors is a related party transaction pursuant to the AIM Rules. Shareholder consent in relation to the grant of the Admission Options and Further Options will be sought at the General Meeting. A further announcement detailing the related party disclosure in relation to the options will be made subsequent to the General Meeting.

For further information, please contact:

Ceres Media International PLC Tel: 020 3178 5622 Alex Dowdeswell / Leslie Barber Nominated Adviser - Cairn Financial Advisers LLP Tel: 020 7148 7900 Jo Turner / Liam Murray Broker - First Columbus LLP Tel: 020 3002 2070

Chris Crawford / Kelly Gardiner

Date   Source Headline
2nd Jun 20267:00 amRNS-RInvestor presentation and SweetBiotix® Sampling
29th May 20267:00 amRNSDirector/PDMR Shareholding
28th May 20267:00 amRNSFinal Results & Notice of AGM
14th May 20267:00 amRNS-RSweetBiotix® Sampling
5th May 20262:30 pmRNSHolding(s) in Company
1st May 202612:00 pmRNSPartial Disposal of Shares in SkinBioTherapeutics
1st Apr 20267:00 amRNSTrading Update
24th Feb 20267:00 amRNSWellBiome® clinical trial on surgical outcomes
17th Feb 20267:00 amRNSStatement: SkinBioTherapeutics Announcement
21st Jan 20267:00 amRNSLarge Order and Record Early Orders for 2026
20th Jan 20267:00 amRNS-RNew Investor Website
2nd Jan 20267:00 amRNSHolding(s) in Company
2nd Jan 20267:00 amRNSHolding(s) in Company
24th Nov 20257:00 amRNSSweetBiotix Overview and Update
17th Nov 20257:00 amRNSOrder with well-known Weight Management Company
13th Oct 20253:31 pmRNSHolding(s) in Company
2nd Oct 20257:00 amRNSDirector/PDMR Shareholding
24th Sep 202512:28 pmRNSDirector/PDMR Shareholding
16th Sep 20257:00 amRNSHalf-year Report
21st Aug 20257:00 amRNSAdmission to Trading on the OTCQB Venture Market
20th Aug 20257:00 amRNSAgreement with Weight Management Company
14th Aug 20257:00 amRNSLaunch of SlimBiome in leading US brand
6th Aug 20254:08 pmRNSResult of AGM
6th Aug 20257:00 amRNSIssue of Options
28th Jul 20257:00 amRNSTrading update
30th Jun 20257:00 amRNSChange of Broker
30th Jun 20257:00 amRNSFinal Results
11th Jun 20257:00 amRNS-RSlimBiome® study in European Journal of Nutrition
23rd May 20257:00 amRNSPlacing and Issue of Warrants
20th May 20257:00 amRNSLaunch of SlimBiome products with US partner
15th Apr 20257:00 amRNSFirst order from US weight management brand
7th Apr 20255:34 pmRNSHolding(s) in Company
18th Mar 20257:00 amRNSCommercial Update
18th Feb 20257:00 amRNSLaunch of Daily Nouri FeelFull product in America
20th Jan 20257:00 amRNS-RLaunch of products on Amazon India
8th Jan 20257:00 amRNSDirectorate Change
20th Dec 202412:00 pmRNSIssue of Options
12th Dec 20242:45 pmRNSHolding(s) in Company
3rd Dec 20247:00 amRNSLaunch of Dr Morepen LightLife in India
30th Oct 20247:00 amRNSRequisition update
25th Oct 20244:29 pmRNSHolding(s) in Company
24th Oct 20247:00 amRNSTotal Voting Rights
23rd Oct 20247:00 amRNSDirectorate Change
18th Oct 20247:00 amRNSResponse to Publication of Circular by ProBiotix
10th Oct 20247:00 amRNSSlimBiome study update
27th Sep 20247:00 amRNSHalf-year Report
26th Sep 20247:00 amRNSResponse to Probiotix Health requisition notice
5th Sep 202410:32 amRNSProBiotix Health plc Fundraise
20th Aug 20247:00 amRNSCommercial update
8th Aug 202412:29 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.